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Abstract
Background: Modified Vaccinia virus Ankara (MVA) is a safe, highly attenuated orthopoxvirus that is being developed as a
recombinant vaccine vector for immunization against a number of infectious diseases and cancers. However, the expression
by MVA vectors of large numbers of poxvirus antigens, which display immunodominance over vectored antigens-of-interest
for the priming of T cell responses, and the induction of vector-neutralizing antibodies, which curtail the efficacy of
subsequent booster immunizations, remain as significant impediments to the overall utility of such vaccines. Thus, genetic
approaches that enable the derivation of MVA vectors that are antigenically less complex may allow for rational
improvement of MVA-based vaccines.
Principal Findings: We have developed a genetic complementation system that enables the deletion of essential viral
genes from the MVA genome, thereby allowing us to generate MVA vaccine vectors that are antigenically less complex.
Using this system, we deleted the essential uracil-DNA-glycosylase (udg) gene from MVA and propagated this otherwise
replication-defective variant on a complementing cell line that constitutively expresses the poxvirus udg gene and that was
derived from a newly identified continuous cell line that is permissive for growth of wild type MVA. The resulting virus,
MVADudg, does not replicate its DNA genome or express late viral gene products during infection of non-complementing
cells in culture. As proof-of-concept for immunological ‘focusing’, we demonstrate that immunization of mice with
MVADudg elicits CD8+ T cell responses that are directed against a restricted repertoire of vector antigens, as compared to
immunization with parental MVA. Immunization of rhesus macaques with MVADudg-gag,audg
2 recombinant virus that
expresses an HIV subtype-B consensus gag transgene, elicited significantly higher frequencies of Gag-specific CD8 and CD4
T cells following both primary (2–4-fold) and booster (2-fold) immunizations as compared to the udg
+ control virus MVA-
gag, as determined by intracellular cytokine assay. In contrast, levels of HIV Gag-specific antibodies were elicited similarly in
macaques following immunization with MVADudg-gag and MVA-gag. Furthermore, both udg
2 and udg
+ MVA vectors
induced comparatively similar titers of MVA-specific neutralizing antibody responses following immunization of mice (over a
4-log range: 10
4–10
8 PFU) and rhesus macaques. These results suggest that the generation of MVA-specific neutralizing
antibody responses are largely driven by input MVA antigens, rather than those that are synthesized de novo during
infection, and that the processes governing the generation of antiviral antibody responses are more readily saturated by
viral antigen than are those that elicit CD8+ T cell responses.
Significance: Our identification of a spontaneously-immortalized (but not transformed) chicken embryo fibroblast cell line
(DF-1) that is fully permissive for MVA growth and that can be engineered to stably express MVA genes provides the basis
for a genetic system for MVA. DF-1 cells (and derivatives thereof) constitute viable alternatives, for the manufacture of MVA-
based vaccines, to primary CEFs – the conventional cell substrate for MVA vaccines that is not amenable to genetic
complementation strategies due to these cells’ finite lifespan in culture. The establishment of a genetic system for MVA, as
illustrated here to allow udg deletion, enables the generation of novel replication-defective MVA mutants and expands the
repertoire of genetic viral variants that can now be explored as improved vaccine vectors.
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Modified Vaccinia virus Ankara (MVA), an attenuated strain of
vaccinia virus that was originally developed as a smallpox vaccine,
was obtained following extensive serial passage on primary chicken
embryo fibroblasts (CEFs) [1]. During this process of attenuation,
MVA underwent deletion of 31 kb (,15%) of its genome, as
compared to its parental strain, including a number of genes that
contribute to viral evasion from host immune responses and that
determine virus host range [2,3]. As a result, MVA is unable to
replicate productively in most mammalian cell types, including
primary human cells. This block occurs at the relatively late stage
of virion assembly and maturation (ie following expression of early
(E), intermediate (I), and late (L) viral genes) [4,5,6,7]. The
resulting inability of MVA to undergo more than one infection
cycle in a human host has imbued this virus with inherent safety
that was demonstrated historically through the immunization of
,120,000 individuals during the smallpox eradication campaign.
More recently, the safety of MVA has been demonstrated in pre-
clinical studies of immune-deficient mice and immune-suppressed
macaques [8,9] and in phase-I clinical trial evaluations of MVA as
a next-generation smallpox vaccine [10].
The desirable safety profile exhibited by MVA, in concert with its
ability to express high levels (and large numbers) of foreign genes,
has rendered MVA a leading candidate for evaluation as a vaccine
vector against an array of infectious diseases and human cancers.
On a number of different fronts, MVA-based vaccines against
HIV/AIDS [11,12,13,14,15,16], malaria [17,18], tuberculosis
[19,20], HPV-induced CIN [21,22], and melanoma [23] are being
evaluated in human clinical trials. Such broad interest to develop a
diverse array of MVA-based vaccines provides substantial oppor-
tunities to engineer MVA vectors to enhance their immunogenicity
– but, to date, these have been largely unrealized.
The utility of MVA-based vaccines to prime immune responses
against heterologous antigens appears to be limited due to
unfavorable competition for immunodominance between the
relatively large number of vector-specific gene products (177 [3])
and the dramatically smaller number of intended vaccine antigens
[24]. Moreover, repeated administration of recombinant MVA
vaccine vectors typically results in an increasingly diminished
efficacy of such booster immunizations, presumably due to the
elicitation of vector-specific neutralizing antibody responses
[25,26,27]. Disappointing results from a phase I clinical trial of
an MVA-based AIDS vaccine [28,29] suggest that there is a
substantial need to better understand the mechanisms governing
antigen presentation [30,31], immunodominance [32], and the
generation of vector-specific humoral immunity [33] in order to
improve upon the immunogenicity of currently available MVA
vaccine vectors.
One approach towards overcoming these limitations is to block
progression of the viral replication cycle at an earlier stage than
normally occurs with MVA infection. This genetic restriction of
viral gene expression would effectively reduce the overall number
of irrelevant, but potentially immunodominant, MVA gene
products that are synthesized during infection. These include
virion structural proteins, which are synthesized with predomi-
nantly late kinetics during infection, that also contain epitopes
targeted by neutralizing antibody responses. In this way, deletion
of an essential MVA gene(s) could augment the immunogenicity of
MVA-based vaccine vectors by effectively reducing the antigenic
complexity of the vector, which could focus cellular and/or
humoral immune responses away from irrelevant (or even
undesirable) antigenic targets of the vector itself and toward the
antigen of interest.
Replication-defective mutants of other large DNA viruses,
including herpes simplex virus [34,35,36,37], adenovirus [38], and
vaccinia virus [39], have been produced for use as vaccine vectors,
but this approach has not yet been feasible with MVA. This
absence of a system for genetic complementation of deletion (or
mutation) of essential genes from MVA derives in large part from
the fact that MVA is routinely propagated on primary CEFs,
which, due to their finite lifespan in culture, are not suitable for
long-term (multi-passage) genetic complementation.
In the present study, we describe the establishment of a genetic
system to complement deletion of essential MVA genes and its use
to create a recombinant MVA from which the uracil-DNA-
glycosylase gene has been deleted. This virus, MVADudg, exhibits
an immune-response phenotype that is distinct from wild type
MVA. This system was predicated on the identification of an
immortalized CEF-derived cell line (UMNSAH/DF-1, ‘‘DF-1’’
[40,41]) that supports high-level growth of MVA and that could be
engineered to constitutively express udg, and presumably, other
MVA genes. Importantly, DF-1 cells (and derivatives thereof) are
attractive alternatives to primary CEFs for large-scale production
of MVA-based vaccines because of their origin through sponta-
neous immortalization, rather than oncogenic transformation, of
embryonic fibroblasts derived from chickens that were free from
endogenous retroviruses [40,41]. As a proof-of-concept, we
demonstrate that immunization of mice with MVADudg elicits
CD8+ T cell responses against fewer MVA vector antigens than
does wild type MVA, thereby constituting an effective focusing of
the antiviral CD8+ T cell repertoire toward antigens that are
expressed early, rather than late, during the MVA replication
cycle. We further show that immunization of rhesus macaques
with MVADudg-gag,audg
2 vector that expresses an HIV gag
transgene from an early viral promoter, elicits significantly higher
(2–4-fold) frequencies of HIV Gag-specific CD8 and CD4 T cells
following primary and booster immunizations, as compared to a
udg
+ control (MVA-gag). In contrast to its positive effects on
transgene-specific T cell responses, deletion of udg from recombi-
nant MVA vectors had no discernable impact on the magnitudes
of transgene-specific antibody responses that were elicited in
rhesus macaques or on the MVA-specific antibody responses that
were elicited in either mice or macaques.
Results
The DF-1 fibroblast cell line supports high-level growth
of MVA
Given that an immortalized cell line is a prerequisite for any
viral genetic complementation strategy, we first sought to identify a
cell line that was able to support MVA replication efficiently and
that might also be suitable for ultimate manufacture of licensable
MVA-based vaccines. Based on their derivation and character, we
reasoned that the CEF-derived DF-1 cell line might be a
promising cell substrate for MVA vector preparation and
propagation. We first assayed the ability of DF-1 fibroblasts to
support the growth of MVA in comparison with two other
permissive cell types, primary CEFs and BHK-21 cells (Figure 1).
Cells were infected with MVA at a ratio of 3 infectious units per
cell, and MVA yields were calculated via TCID50 determination
on primary CEFs (Figure 1A) or via plaque assay on DF-1 cells
(Figure 1B) at the indicated times following infection. Following
the expected period of viral eclipse at 2 hours post-infection, MVA
infection resulted in the net production of approximately 10
8
infectious units per million DF-1 cells by 24 hours post-infection.
The yields of MVA from infected DF-1 cells were equivalent to
those obtained following infection of primary CEF or BHK-21
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MVA growth and support virus growth to levels that are
comparable to those obtained through propagation of MVA on
primary CEFs.
Zeocin-resistance/GFP-positivity allows for rapid isolation
of MVA recombinants
A number of methods that facilitate selection or screening for
recombinant vaccinia virus are also applicable for the isolation of
recombinant MVA. These include expression of drug resistance
markers (gpt [42,43], neo [44,45], puro [46]) whose transient or
stable expression from the viral genome allow for enrichment of
drug-resistant recombinant viruses, and expression of genes (lacZ ,
gfp [45], gus [47]) whose products may be detected via fluorescence
or colorimetric assays to expedite the identification and isolation of
recombinant viruses. We sought to evaluate the use of zeocin [48],
an antibiotic whose mechanism of action rests upon its ability to
intercalate into DNA and subsequently cleave DNA molecules, as
a new antibiotic selection to facilitate the prompt isolation of MVA
and vaccinia recombinants. Zeocin was found to be a potent
inhibitor of MVA growth. Addition of this antibiotic to the culture
medium of MVA-infected DF-1 cells at concentrations ranging
from 50–200 mg/ml reduced MVA yields between 82–98% as
compared to growth in the absence of the drug (not shown).
To demonstrate that zeocin selection could be used to facilitate
isolation of recombinant viruses, we recombined a DNA cassette
that directs early expression of the gfpzeo fusion gene, which
encodes an N-terminal green fluorescent protein (GFP) in frame
with a C-terminal zeocin-resistance polypeptide (Sh ble gene
product [49] ), at deletion site III of the MVA genome (Figure 2A)
and selected for zeocin-resistant recombinants. Microscopic
visualization of recombinant GFP
+ plaques at 2 days following
infection of DF-1 cells in the presence of zeocin (Figure 2B)
enabled rapid plaque isolation and subsequent iterative plaque
purification of the viral recombinant MVA-gz (Figure 2A). Thus,
simultaneous drug selection and visual screening for GFPZEO
+
plaques expedites the isolation and preparation of recombinant
MVA viruses.
Generation and characterization of MVADudg
Vaccinia virus-encoded uracil-DNA-glycosylase is essential for
VV growth. [50,51,52,53,54]. Because MVA is derived from
vaccinia virus (strain CVA) and UDG
MVA shares complete amino
acid identity with UDG encoded by other vaccinia strains
(Copenhagen, Western Reserve), it was expected that udg would
also be essential for MVA growth and that its deletion would
require a genetic complementation strategy. An initial step
towards deleting udg from MVA was to generate an MVA-
permissive cell line that also expresses UDG at levels sufficient to
complement genomic deletion of udg. MVA-permissive DF-1 cells
(Fig. 1) were transfected with a udg-expression plasmid pCANudg
(see materials and methods) and G418-resistant cell clones were
screened for their ability to complement the growth of ts4149, a
vaccinia virus mutant that harbors a temperature sensitive
Figure 1. DF-1 cells support high-level growth of MVA. (A) MVA
yields following infection of DF-1 fibroblasts and 1u CEFs at MOI=3.
Data represent the means of duplicate samples. (The MVA stock was
grown and titered on 1u CEFs). (B) MVA yields following infection of DF-
1 fibroblasts, 1u CEFs, and BHK-21 cells at MOI=3. Data represent the
means of triplicate samples 61 standard deviation. (The MVA stock was
grown and titered on DF-1 cells).
doi:10.1371/journal.pone.0005445.g001
Figure 2. Construction and characterization of MVA-GZ. (A)
Genome map of MVA recombinant MVA-gz (top), which encodes gfpzeo
(gz) under the control of an early modified H5 promoter (pH 5). Roman
numerals (I-VI) represent the sites of the major genomic deletions in
MVA as compared to its parental strain [3]. *=vaccinia virus early
transcriptional stop signal (59-TTTTTCT-39) [70]. (B) Recombinant (MVA-
gz) plaques visualized via fluorescence microscopy as GFP
+ plaques on
DF-1 cells at 4 days following infection; original magnification=4X.
doi:10.1371/journal.pone.0005445.g002
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temperature of 39.5uC (not shown). A clonal cell line that
supported high-level replication of ts4149 at the non-permissive
temperature was designated CAN20 and used as the cellular
substrate to generate MVADudg recombinants. To delete udg from
MVA, plasmid transfer vectors pDudgdloxPH5gz-A, -B, which
differ from each other only in the orientation of their pH5-gfpzeo
expression cassettes, were constructed to direct replacement of the
udg ORF with a loxP-flanked gfpzeo expression cassette. MVA-
infected CAN20 cells were transfected with pDudgdloxPH5gz-A or
pDudgdloxPH5gz-B (as described, materials and methods) and
GFP
+/zeocin-resistant recombinants were plaque purified
through 4 rounds of zeocin selection. The genotypes of two
independent MVADudg recombinants, vDG013 and vDG014
(Figure 3A), that harbor gfpzeo expression cassettes in opposite
orientations at the udg locus were confirmed via Southern blot and
shown to be free from contamination with wild type (parental)
MVA (Figure 3B).
MVADudg recombinants grow only on udg-
complementing cells
To confirm that we had deleted an essential viral gene from
MVA, we first compared the abilities of 2 independent MVADudg
isolates and MVA-gz (udg
+) to grow on UDG-complementing cells
or parental DF-1 cells (Figure 4). MVA-gz is a udg
+ MVA
recombinant that expresses the gfpzeo fusion gene (Figure 2B).
UDG-complementing cells (CAN20 cells) (Figure 4A) or DF-1
fibroblasts (Figure 4B) were infected with MVADudg isolates
vDG013, vDG014, or with (udg
+) MVA-gz at a virus/cell ratio of 3,
and virus yields were determined by plaque assay on CAN20 cells
at the indicated times following infection. Both MVADudg isolates
exhibited virus yields equivalent to those seen with (udg
+) MVA-gz
during infection of CAN20 cells (Figure 4A). In contrast, neither
MVADudg isolate exhibited any net increase in virus yield during
infection of non-complementing cells, whereas MVA-gz replicated
to high titers of approximately 10
8 PFU per million DF-1 cells,
confirming that udg is essential for MVA growth.
Figure 3. Isolation of MVADudg recombinant viruses. (A) Genome maps of wild type MVA and udg-deletion MVA recombinants with restriction
fragment lengths in kilobases (kB). The StuI and KpnI restriction sites in wild type MVA denote genomic nucleotide positions 89,347 and 93921,
respectively. (B) Diagnostic Southern blots that confirm genotypes of MVADudg isolates.
doi:10.1371/journal.pone.0005445.g003
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of viral late genes
In vaccinia virus infections, UDG has an essential role in viral
DNA synthesis that is independent of its glycosylase activity [54].
To confirm that deletion of udg from the MVA genome also results
in a block to viral DNA replication, we monitored DNA
replication via microscopic detection of bromodeoxyuridine
(BrdU) incorporation into newly-synthesized DNA within infected
cells. MVADudg recombinant virus vDG020- , MVA- , or mock-
infected UDG-complementing (CAN20) and non-complementing
(DF-1) cells were labeled with BrdU between 2–6 hours following
infection (Figure 5). Cytoplasmic foci containing newly synthesized
MVADudg DNA were observed only during infection of udg-
complementing CAN20 cells (Figure 5F) and were not observed
during MVADudg infection of non-complementing DF-1 cells
(Figure 5B). In contrast, MVA infection of both CAN20 and DF-1
cell lines resulted in the generation of cytoplasmic viral DNA
replication centers (Figure 5A, 5E) that were absent when these
infections were performed in the presence of araC, an inhibitor of
viral DNA synthesis (Figure 5C, 5G).
Because the expression of viral late genes is dependent upon
viral DNA synthesis, we also determined the level of late gene
expression during MVADudg infection of either complementing
or non-complementing cells. SDS-PAGE resolution of infected
cell proteins that were radiolabeled with
35S-methionine during
MVADudg (vDG014)-, MVA(udg
+)-, or mock-infection of
CAN20 and DF-1 cells demonstrated a defect in the
production of the protein products of several late genes
during MVADudg-infection of non-complementing DF-1 cells
(Figure 6).
MVADudg immunization elicits CD8+ T cell responses
against fewer vector antigens than does parental MVA
Because MVADudg was blocked at the ERL transition during
infection of non-complementing cells in culture, we determined
whether this abrogated in vivo CD8+ T cell responses directed
against viral late gene products following immunization of mice.
To measure these responses, mice were immunized with
MVADudg or parental MVA and their splenic CD8+ T cell
responses characterized at 7 days post-immunization via
intracellular cytokine staining (ICS) assay, which utilized an
epitope panel comprised of recently-defined CD8+ determinants
[55] representing both Early and Late viral antigens (Figure 7).
Representative flow cytometry plots of CD8+ splenocytes that
produce IFNc following ex vivo peptide stimulation are shown
(Figure 7A). The frequencies of epitope-specific CD8+ T cell
responses, determined for individual mice, are shown following
immunization with 10
6 PFU (Figure 7B) or 10
8 PFU (Figure 7C)
of either MVADudg or wild type MVA control, as indicated.
Following immunization of mice at the lower dose (10
6 PFU),
MVADudg elicited 14-fold and 9-fold lower frequencies of CD8+
T cells against the A3L270–277 (Late) and A19L47–55 (Unknown)
determinants, respectively, than did MVA, which were deter-
mined to be statistically significant differences (Mann-Whitney
test). In contrast, the average frequencies of CD8+ T cells
directed against A42R88–96 (0.05% MVA, 0.05% MVADudg),
B8R20–27 (2.6% MVA, 1.9% MVADudg), or K3L6–15 (0.07%
MVA, 0.08% MVADudg) were not significantly different between
groups. Similarly, following immunization of mice at the higher
dose (10
8 PFU), both MVADudg and MVA elicited similar
frequencies of A42R88–96-, B8R20–27-, or K3L6–15-specific CD8+
T cells, which were $3-fold higher than the corresponding
frequencies that were elicited following 10
6 PFU immunization.
Interestingly, immunization with MVADudg at the high dose (10
8
PFU) overcame the deficit of A3L270–277-restricted T cells that
was observed following immunization with 10
6 PFU MVADudg,
but did not abrogate the elicitation of a relatively lower
frequency of A19L47–55-restricted CD8+ T cells, as compared
to MVA (MVADudg=0.09%, MVA=0.22%, average No Stim/
limit of detection=0.07%). Because the A3L protein is a
structural component of the MVA virion (and therefore present
in the viral inoculum), our observation that A3L270–277-restricted
CD8+ T cells are elicited by MVADudg only following a
relatively high-dose immunization is most readily explained as a
result of cross presentation of A3L antigen from the input virus,
rather than de novo synthesized A3L antigen.
Figure 4. MVADudg recombinants grow on the DF-1-derived
udg-complementing cell line (CAN20), but do not grow on
parental DF-1 cells. Yields of MVADudg recombinants vDG013,
vDG014, and udg
+ recombinant MVA-gz were determined at the
indicated times following infection of CAN20 cells (A) or DF-1 cells (B) at
a ratio of 3 PFU per cell. Cell cultures were frozen at indicated times
following infection and subsequently thawed, sonicated, and clarified
by centrifugation (800 g). Virus titers were determined via plaque assay
on CAN20 cells. Data represent the means of duplicate samples; error
bars represent the ranges.
doi:10.1371/journal.pone.0005445.g004
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elicits similar titers of vector-specific neutralizing
antibodies
Because many late viral genes encode virion structural
components that embody B cell epitopes that engender neutral-
izing antibody (NAb) responses, we sought to determine whether
abrogation of de novo late gene expression during in vivo infection,
via udg deletion, might attenuate the overall magnitude of the
resulting neutralizing antibody response that is generated against
the MVA vector. Groups of mice were immunized with MVADudg
or MVA and their anti-MVA serum neutralizing antibody titers
were determined 28 days later (Figure 8). Representative flow
cytometry plots (Figure 8A) and corresponding serum dilution:re-
sponse curve (Figure 8B), which illustrate the titration of
neutralizing antibodies in this assay, are shown and include
goodness-of-fit (R
2) and EC50 NAb titer values derived from the
non-linear regression analysis. The MVA-specific NAb (EC50)




8 PFU of either MVADudg or
MVA (Figure 8C). No statistical differences in neutralizing
Figure 6. MVADudg does not express viral late genes during infection of non-complementing cells in culture. DF-1 and udg-
complementing (CAN20) cells were infected with MVA (udg
+) or MVADudg isolate vDG014 (D) at MOI=10 in the absence or presence of the DNA
synthesis inhibitor AraC (150 mM), as indicated. Infected cell proteins were metabolically labeled with
35S-methionine for 30 min immediately prior to
harvesting at indicated times post infection. Proteins were separated via SDS-PAGE and visualized by autoradiography. Arrows denote viral late gene
products as defined via AraC-mediated inhibition of expression.
doi:10.1371/journal.pone.0005445.g006
Figure 5. MVADudg does not exhibit DNA replication during infection of non-complementing cells. DF-1 cells (A, B, C, D) and CAN20
cells (E, F, G, H) were infected either with MVA in the absence (A, E) or presence (C, G) of the DNA synthesis inhibitor AraC (150 mM), MVADudg
(vDG020) in the absence of AraC (B, F), or were mock infected (D, H) and labeled with BrdU between 2–6 hours following infection. Arrows denote
cytoplasmic foci of viral DNA replication and arrowheads denote cell nuclei.
doi:10.1371/journal.pone.0005445.g005
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given immunization dosage group, or for either MVA or
MVADudg across immunization dosage groups. These data suggest
that any contribution of de novo synthesized viral late gene products
to the development of global vector-specific neutralizing antibody
titers is negligible, and that such NAb responses are fully primed
in vivo by relatively low amounts (ie containing #10
4 PFU) of input
viral inocula.
Immunization of rhesus macaques with MVADudg-gag
elicits enhanced frequencies of CD8 and CD4 T cells that
are specific for the expressed HIV gag transgene
We next sought to determine whether an MVA vector that is
deleted for udg elicits enhanced T cell responses against an
expressed heterologous antigen, as compared to a udg
+ control
virus, in a population of MHC-diverse rhesus macaques. Towards
this end, we constructed MVADudg-gag and MVA-gag, which
Figure 7. Immunization of mice with MVADudg elicits CD8
+ T cell responses directed against early, but not late viral gene products.
(A) Representative intracellular cytokine staining (ICS) of peptide-stimulated splenocytes at 7 days following immunization with MVA or MVADudg,a s
indicated. Splenocytes were stimulated ex vivo with 0.5 uM of A3L270–277, B8R20–27, or A19L47–55 peptide for 5 hours in the presence of GolgiPlug
secretion inhibitor and stained with fluorescently-labeled antibodies for flow cytometric analysis. Plots represent data from individual mice and
denote the percentages of IFNc-positive CD3+CD8+ splenocytes expressed as fractions of their corresponding overall CD3+CD8+ splenocyte
populations. (B) Splenocytes from mice immunized with MVA (circles) or MVADudg (triangles) were analyzed by ICS assay (as above) following ex vivo
stimulation with 0.5 mM A3L270–277, A42R88–96, B8R20–27, K3L6–15, or A19L47–55 peptide, or no stimulation, to determine the frequencies of antiviral
CD8+ T cells present at 7 days following immunization. Data are organized by the kinetic class (Late, Early, or Unknown [Unk]) to which each viral
gene belongs. Symbols represent data from individual mice; horizontal lines represent group means. Each dosage group (10
6,1 0
8 PFU) presents data
obtained from two independent immunization experiments. Statistical comparison of MVA vs MVADudg groups, for each CD8+ T cell epitope, was
performed via nonparametric Mann-Whitney analysis; only P-values #0.05 are shown.
doi:10.1371/journal.pone.0005445.g007
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subtype-B consensus gag gene from an early viral promoter at
MVA deletion site-III and differ only in their udg genotype, and
used these viruses to immunize two groups of rhesus macaques
(N=6/group) with 2610
8 PFU of virus at 0, 6, and 12 weeks. At
various times, both preceding and following immunization, we
determined the frequencies of Gag-specific CD8 and CD4 T cells
in PBMC via intracellular cytokine assay for the production of
IFNc and IL2 in response to ex vivo stimulation with a pool of
matched overlapping Gag peptides (Figure 9). By 4 weeks
following primary immunization, macaques immunized with
MVADudg-gag exhibited significantly greater frequencies of Gag-
specific CD8 T cells, which produced IFNc in response to Gag
peptide stimulation, than did animals immunized with MVA-gag
(MVADudg-gag: range=0.04–0.39, median=0.094; MVA-gag:
range=0.01–0.07, median=0.033) (Figure 9A). Relatively low
frequencies of Gag-specific/IL2-producing CD8 T cells were
observed following primary immunization with either virus
Figure 8. Immunization of mice with MVADudg elicits MVA-specific neutralizing antibody responses that are of magnitudes similar
to those elicited by MVA. (A) Representative flow cytometric data from the GFP fluorescence-based MVA neutralization assay. Serial dilutions of
serum from a mouse immunized 28 days earlier with 10
6 PFU MVA were mixed with a constant amount of GFP-expressing virus MVA-gz and
incubated for 1 hour at 37uC. HeLa cells were then added to individual serum:virus mixtures, incubated overnight at 37uC, and analyzed for GFP
expression by flow cytometry. The gated percentages of GFP+ cells (shown) were also normalized to the average maximum response observed for
cells infected with MVA-gz in the absence of test serum (normalized values expressed as percentages of the maximum response are shown
parenthetically). Illustrative data representing serum dilutions 1:16, 1:256, 1:512, and 1:8,192, which constitute a subset of all serum dilutions
analyzed, are shown. (B) Representative nonlinear regression analysis for the determination of EC50 neutralizing antibody (NAb) titers. Replicate
normalized GFP+ response data from an individual mouse (described in (A)) was analyzed by non-linear regression. Goodness-of-fit value (R
2) and the
EC50 NAb titer, expressed as the dilution factor, are shown. (C) Mice were immunized once with the indicated doses of MVA (circles) or MVADudg
(triangles). Titers of MVA-specific neutralizing antibodies were determined, as described above, for serum samples collected 28 days following
immunization. Symbols represent NAb titers that were determined for individual mice; horizontal lines represent group means. Statistical comparison
of MVA vs MVADudg groups, within each dosage group, was performed via nonparametric Mann-Whitney analysis and did not result in any
significant (P#0.05) differences.
doi:10.1371/journal.pone.0005445.g008
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responses, MVADudg-gag elicited significantly higher frequencies of
IL2-producing CD4 T cells at 4 weeks post-immunization than did
MVA-gag (MVADudg-gag: range=0.12–0.46, median=0.21;
MVA-gag: range=0–0.18, median=0.087) (Figure 9D). Effective
boosting of both Gag-specific CD8 and CD4 T cell responses was
observed at one week following the second immunization (1
st
booster immunization) in both groups of immunized macaques,
but was significantly more pronounced (group median responses
were approximately 2-fold higher) in those macaques that were
Figure 9. Immunization of rhesus macaques with MVADudg-gag elicits significantly higher frequencies of HIV Gag-specific CD8 and
CD4 T cells. Rhesus macaques (N=6/group) were immunized at 0, 6, and 12 weeks with MVADudg-gag or MVA-gag (2610
8 PFU per immunization).
At the indicated times, PBMC samples were either stimulated ex vivo with a pool of matched overlapping HIV Gag peptides, or were not stimulated,
and the frequencies of IFNc- and IL2-producing CD8 and CD4 T cells were determined by intracellular cytokine staining/flow cytometric analysis as
described. The frequencies of CD8 (A, C) and CD4 (B, D) T cells that co-expressed IFNc (A, B) or IL2 (C, D) and the activation marker CD69 are shown.
Symbols represent the means of replicate samples assayed for individual macaques; horizontal lines denote group medians. Statistical comparison of
groups immunized with MVADudg-gag vs MVA-gag was performed at each timepoint via non-parametric Mann-Whitney analysis. P-values ,0.07 are
indicated as shown. Immunizations are denoted by vertical dashed lines.
doi:10.1371/journal.pone.0005445.g009
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gag (Figure 9A, B, D). No effective boosting was subsequently
observed in either group following the third immunization (2
nd
booster immunization) and likely reflects efficient neutralization of
the viral inocula due to the high levels of MVA-specific
neutralizing antibodies that were present in all animals this time
(see below). Taken together, these data indicate that macaques
immunized with a Dudg vaccine vector mounted significantly,
albeit modestly, higher frequenicies of transgene-specific CD8 and
CD4 T cell responses at various times following both primary and
booster immunizations, as compared to those animals immunized
with a control udg
+ vector.
Immunization of rhesus macaques with MVADudg-gag
and MVA-gag elicits similar titers of HIV Gag-specific
antibodies
Plasma samples from macaques immunized with MVADudg-gag
or MVA-gag were assayed to determine whether the relatively
higher frequencies of Gag-specific CD4 T-helper cellular respons-
es that were elicited by MVADudg-gag correlated with higher levels
of Gag-specific antibodies in vivo. Titers of HIV Gag-specific
binding antibodies were determined by ELISA utilizing recombi-
nant baculovirus-expressed HIV Gag protein as the coating
antigen and are shown for macaques immunized with MVADudg-
gag (Figure 10A) and MVA-gag (Figure 10B). Levels of Gag-specific
antibodies were similarly detected in both immunization groups
beginning two weeks following primary immunization. Effective
boosting of these titers was observed in all macaques following the
second immunization (1
st booster immunization), but to a lesser
extent following the third immunization (2
nd booster immuniza-
tion). Comparison of Gag-specific ELISA titers between immuni-
zation groups at any given time following immunization with
MVADudg-gag versus MVA-gag revealed no significant differences
(Mann-Whitney).
Immunization of rhesus macaques with MVADudg-gag
and MVA-gag elicits similar titers of vector-specific
antibody responses
Plasma samples from macaques immunized with MVADudg-gag
or MVA-gag were assayed to determine whether the abrogation of
late viral gene expression during in vivo infection, conferred via
deletion of udg from MVADudg-gag, might attenuate the magnitude
of antibody responses directed against the MVA vector itself.
Endpoint titers of MVA-binding antibodies were determined by
ELISA utilizing whole MVA virions as the coating antigen, and
are shown for macaques immunized with MVADudg-gag
(Figure 11A) and MVA-gag (Figure 11B). MVA-specific neutral-
izing antibody (NAb) titers (EC50) were determined by utilizing a
plate-based MVA-lacZ infection-inhibition assay (which has
relatively higher sample throughput as compared to the flow
cytometry-based MVA-gfpzeo assay used above in our murine
studies) and are shown for macaques immunized with MVADudg-
gag (Figure 11C) and MVA-gag (Figure 11D). Within each
immunization group, MVA-specific antibody titers (both binding
and neutralizing) were detected following primary immunization
and exhibited significant boosting ($1-log) following the second
immunization (1
st booster immunization) and diminished boosting
following the third immunization (2
nd booster immunization).
Comparison of MVA-specific ELISA titers, or MVA-specific NAb
titers, between groups of macaques at any given time following
immunization with MVADudg-gag versus MVA-gag revealed no
significant differences in the antibody responses that were elicited
by the udg-deletion and udg
+ vectors.
Discussion
There is a substantial need to improve the immunogenicity of
MVA-based vaccines, which are currently being developed for use
against a number of prominent infectious diseases including AIDS,
malaria, and tuberculosis, as well as human cancers. Engineered
MVA vectors, which help focus cellular immune responses away
from vector-specific poxvirus antigens and towards heterologous
antigens-of-interest, or which engender weaker vector-specific
neutralizing antibody responses, should exhibit greater utility than
vectors derived from parental MVA for use as vaccines. In the
present study, we describe a genetic system that allows for the
generation and propagation of MVA mutants that have deletions
for essential viral genes, as demonstrated for the deletion of the
poxvirus uracil-DNA-glycosylase gene from the MVA genome.
We provide a proof-of-concept that MVADudg elicits CD8+ T cell
responses against a restricted repertoire of vector antigens in vivo,
as compared to wild type MVA. Furthermore, we demonstrate in
a relevant non-human primate model that a udg
2 AIDS vaccine
vector, MVADudg-gag, elicited 2–4-fold higher frequencies of HIV
Gag-specific CD8 and CD4 T cells in immunized macaques, as
compared to a udg
+ control vector (MVA-gag) that expresses an
identical HIV gag transgene.
Figure 10. Immunization of rhesus macaques with MVADudg-gag elicits HIV Gag-specific antibody responses that are of
magnitudes similar to those elicited by MVA-gag. Rhesus macaques (N=6/group) were immunized at 0, 6, and 12 weeks with MVADudg-gag
or MVA-gag (2610
8 PFU per immunization). At the indicated times, plasma samples were assayed to determine the titers of HIV Gag-specific binding
antibodies via ELISA utilizing recombinant HIV Gag protein as the coating antigen, as described. Symbols represent the mean (of duplicate)
absorbance (A450nm) values that were determined from 1:25 dilutions of plasma samples from individual macaques; black lines denote group mean
absorbance values. Immunizations are denoted by vertical dashed lines. Statistical comparison of groups immunized with MVADudg-gag vs MVA-gag
was performed at each timepoint via non-parametric Mann-Whitney analysis and did not result in any significant (P#0.05) differences.
doi:10.1371/journal.pone.0005445.g010
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identification of the DF-1 chicken embryo fibroblast cell line as
being fully permissive for MVA infection. The DF-1 cell line
possesses a number of desirable attributes that make it a
convenient cellular substrate for the production of MVA
recombinants in the research laboratory. These include: MVA
growth comparable to that achieved with primary CEF cultures,
the ability to plaque MVA on DF-1 cells, and the ability to
generate DF-1-derived cell lines that stably express poxvirus genes
and complement the growth of essential-gene deletion MVA
mutants. In addition, the DF-1 cell line possesses numerous
attributes that make it an attractive alternative to primary CEF
cultures for the production of clinical-grade lots of MVA-based
vaccines. The DF-1 cell line is a spontaneously-immortalized cell
line derived from CEFs prepared from line 0 chicken eggs [40].
These cells lack endogenous avian retroviral sequences and exhibit
a non-transformed phenotype [40]. Indeed, based on their lack of
spontaneous transformation, DF-1 cells are used to score for
transformation by potential oncogenes in avian tumorigenicity
models [41]. Regulatory approval of the DF-1 cell line, or
derivatives thereof, as a cell substrate for use in cGMP
manufacture of MVA-based vaccines would obviate the existing
need for recurrent certification of primary CEF cultures, which
exhibit finite lifespans in culture, and might enable new
approaches to optimize the yield and cost-effectiveness of such
vaccines.
Replication-defective versions of other viral vectors
[35,37,38,56] have been developed for use as vaccine vectors, in
large part to increase vector safety. In contrast, MVA has
historically exhibited a favorable safety profile as a smallpox
vaccine [57] and is unlikely to overcome its host-range restriction
during human infection due to the multiple gene deletions it
acquired during its derivation [3]. Even so, targeted deletion of an
essential gene(s) from MVA will only increase the safety of such
MVA vectors by further reducing any potential for complemen-
tation in vivo.
Interestingly, an approach to generate replication-defective
vectors from MVA has not been pursued. This is likely because
parental MVA undergoes an abortive growth cycle in most cell
types [4,5,6,7] and is commonly propagated on primary CEFs,
which, because of their finite lifespan in culture, are not suitable
for stable genetic complementation of mutant viruses. Despite
reports that the continuous BHK-21 cell line is fully permissive for
MVA replication [6,7], this cell line has not, to our knowledge,
been utilized for genetic complementation of MVA mutants.
Thus, having identified a new cell line that is amenable to
genetic complementation strategies for MVA, we proceeded to
generate a DF-1-derived cell line that constitutively expresses
udg
MVA and to use this cell line to complement deletion of udg from
the MVA genome. Our targeting of udg, rather than another
essential MVA gene, was based partly on initial studies by Holzer
and co-workers that demonstrated the feasibility of trans-
complementation of a udg-deletion in vaccinia virus, and that a
udg-deletion mutant of vaccinia virus, which also expressed the
prM and E structural proteins of tick-borne encephalitis virus
(TBE), was better able to protect mice against lethal TBE
challenge than was a replication-competent VV recombinant
[39,52,58]. While the immune mechanisms that mediated this
enhanced protection, which potentially include increased levels
and/or duration of antigen synthesis from early viral promoters,
greater efficiency of antigen processing and/or presentation within
infected cells, or augmented cross-presentation of antigens due to
the induction of apoptosis in infected cells [30,59,60,61,62], were
not determined, their in vivo observations encouraged our studies to
delete udg from MVA, toward the goal of generating an improved
MVA vaccine vector.
Deletion of udg from MVA resulted in a virus (MVADudg) that is
genetically blocked prior to viral DNA synthesis and late gene
Figure 11. Immunization of rhesus macaques with MVADudg-gag elicits MVA-specific antibody responses that are of magnitudes
similar to those elicited by MVA-gag. Rhesus macaques (N=6/group) were immunized at 0, 6, and 12 weeks with MVADudg-gag or MVA-gag
(2610
8 PFU per immunization). At the indicated times, heat-inactivated plasma samples were assayed to determine the titers of MVA-specific binding
antibodies (A, B) via ELISA utilizing whole MVA virions as the coating antigen, or MVA-specific neutralizing antibodies (C, D) utilizing the MVA-lacZ
neutralization assay, as described. Symbols represent data from individual macaques; black lines denote group geometric mean titers. Immunizations
are denoted by vertical dashed lines. Statistical comparison of groups immunized with MVADudg-gag vs MVA-gag was performed at each timepoint
via non-parametric Mann-Whitney analysis and did not result in any significant (P#0.05) differences.
doi:10.1371/journal.pone.0005445.g011
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blasts. In this regard, the DNA-negative and late gene-negative
phenotypes exhibited by MVADudg during infection of DF-1 cells
are analogous to those observed during infection of non-
complementing cells with a VVDudg mutant [52,54]. Thus, the
growth of udg
2 MVA was restricted to the trans-(udg)-comple-
menting DF-1-derived cell line. As such, restoration of udg to a
udg
2 MVA virus, via genetic recombination, and selection for virus
growth on non-complementing cells should provide a powerful
system to generate and isolate recombinant MVA viruses, as has
been described analogously for the rescue of udg
2 vaccinia
recombinants [58].
With regard to the generation of MVA-specific cellular immune
responses, we hypothesized that genetic preclusion of late MVA
gene expression, via udg deletion, would effect a focusing of T cell
responses towards antigens expressed early, rather than late,
during the MVA infection cycle. Our characterization of the
CD8+ T cell responses elicited in mice following immunization
with either MVA or MVADudg viruses demonstrates, as proof-of-
concept, that genetic abrogation of MVA late gene expression
results directly in the generation of a restricted repertoire of vector-
specific CD8+ T cells that is biased in favor of antigens that are
expressed with early, rather than late, kinetics. This was evidenced
by the reductions in CD8 T cell responses against determinants
encoded within the viral A3L antigen, a known late gene product,
as well as the viral A19L antigen, following immunization with
MVADudg.
With regard to the generation of A3L270–277–specific CD8 T
cells, there are potentially two sources of the amino acid
determinant present during immunization – one from input virion
core proteins (in both infectious and non-infectious virus particles)
and the second from A3L that is synthesized de novo in MVA-, but
not MVADudg-infected cells. As such, the capacity to prime
restricted CD8+ T cells by MVA or MVADudg may be expected to
vary as a function of the input immunization dose. Indeed, our
observations bear this out, as A3L270–277–restricted CD8+ T cells
were elicited by MVA following both low (10
6 PFU) and high (10
8
PFU) dose immunizations, but were only elicited by MVADudg
following the high dose immunization. In contrast, A19L47–55-
restricted CD8+ T cells were not generated following immuniza-
tion with MVADudg at either high or low doses of input virus.
While relatively little is currently known about this gene, our
model predicts that A19L is a late gene that encodes either a non-
structural protein, or a structural protein that does not contain
amino acid residues 47–55, such that the A19L47–55 determinant is
not present in the viral inoculum. Taken together, these findings
indicate that MVADudg elicits a restricted repertoire of vector-
specific CD8+ T cell responses, but suggest that the effectiveness of
such a genetic approach to focus CD8+ responses away from late
viral gene products may be limited under conditions of high-dose
immunization due to the potential to cross-prime CD8+ T cells
with input viral antigens.
However, compensatory increases in the frequencies of CD8+ T
cell responses directed against either of two early viral determi-
nants (B8R20–27, K3L6–15) were not observed following immuni-
zation of mice with MVADudg. In part, this may reflect a model-
specific effect in that the early B8R20–27 determinant already
constitutes the immunodominant CD8+ T cell determinant of
MVA in C57Bl/6 mice and, as such, may not be amenable to
further enhancement via ‘repertoire focusing’. In an analogous
immunization model utilizing MHC-selected (Mamu A*01
+) rhesus
macaques, we have similarly observed that deletion of udg did not
augment the frequencies of CD8 T cells that were elicited by either
of two known immunodominant SIV determinants expressed from
the MVA vector [63]. Alternatively, genetic abrogation of viral
late gene expression may simply reduce the number of different
vector-specific determinants that elicit CD8+ T cell responses,
rather than the magnitudes of the residual responses.
To address this question directly in a relevant vaccine setting,
we conducted an immunization trial in MHC-diverse rhesus
macaques in which the levels of transgene-specific T cells that were
elicited by Dudg and udg
+ MVA vectors that express an identical
HIV gag transgene could be compared directly. As shown,
immunization of macaques with MVADudg-gag resulted in the
generation of 2–4-fold higher frequencies of HIV Gag-specific
CD8 and CD4 T cells, as compared to MVA-gag, at the times of
peak T cell responses following both primary and booster
immunizations. These data demonstrate that, as a vector for
immunizing against a heterologous antigen, the udg
2 recombinant
was modestly more immunogenic than the corresponding udg
+
control.
With respect to the generation of transgene-specific humoral
immune responses, we reasoned that the higher frequencies of
Gag-specific CD4 T-helper cellular responses that were elicited in
macaques by MVADudg-gag might contribute to the generation of
relatively higher titers of Gag-specific antibodies. However, our
results showing the generation of Gag-specific antibodies with
similar titers and with similar kinetics, following immunization of
macaques with MVADudg-gag or MVA-gag recombinants, indicate
that deletion of udg had neither beneficial nor detrimental effects in
this regard. Thus, the positive effects of udg deletion on transgene-
specific immunity were observed for T cell, rather than humoral,
immune responses.
With regard to the generation of MVA-specific humoral
immune responses, we originally hypothesized that abrogation of
late gene expression, via udg deletion from MVA vectors, would
result in the generation of reduced levels of vector-specific
neutralizing antibodies. Analogous to the dual sources of CD8+
T cell determinants for viral structural antigens, there are
potentially two sources of relevant B cell epitopes that can elicit
vector-specific neutralizing antibody responses. These include
virion structural proteins that are either associated with input virus
or are synthesized de novo within infected cells. Because such
structural proteins are typically synthesized during infection with
predominantly late kinetics, it was reasonable to originally
hypothesize that MVADudg might elicit reduced titers of vector-
specific neutralizing antibodies, as compared to wild type MVA.
However, our results indicate that deletion of udg had no
demonstrable effect on the overall levels of MVA-specific
antibodies that were generated in vivo, in either mice or rhesus
macaques, following immunization with Dudg or udg
+ vectors. In
mice, no significant differences were observed between the titers of
MVA-specific NAbs that were elicited by either MVADudg or
MVA following immunization over a 4-log range of input virus
(10
4–10
8 PFU). This relatively shallow dose-response relationship
between input virus dose and ensuing vector-specific NAb titers
suggests that these NAb responses are fully generated by relatively
low amounts (containing #10
4 PFU) of input viral inocula.
Whether a similar dose-response relationship would be observed
following immunization of mice by different anatomical routes, or
in other species, is under investigation. Additionally, the
magnitudes and kinetics of MVA-specific antibody responses
(both virion-binding and neutralizing) were virtually identical
between Dudg and udg
+ vectors following both primary and booster
immunizations of rhesus macaques.
Our observations that Dudg and udg
+ MVA vectors elicit similar
levels of vector-specific antibodies in vivo are consistent with
those of Ober, et al that showed comparable levels of vaccinia
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zation with replication-defective (Dudg) vaccinia virus (dVV-L,
strain Lister), replication-competent vaccinia (VV-L), or MVA
[64]. Interestingly, a subsequent study by this group showed the
levels of vector-specific antibodies elicited in mice by MVA to be
relatively lower than those elicited by the replication-defective
dVV-L virus [65].
Taken together, our results suggest that any contribution of de
novo synthesized viral late gene products to the net MVA-specific
antibody response in vivo is negligible. Given the demonstration
that vaccinia-specific antibodies are both necessary and sufficient
to confer protection against virulent monkeypox challenge in non-
human primates [66], our finding that levels of MVA-specific
NAbs may be driven predominantly by input viral antigens should
help inform our understanding of the mechanism by which next-
generation smallpox vaccines elicit protection.
In conclusion, we feel that the genetic system that we have
developed provides a platform for the development of a new
generation of MVA-based vaccine vectors that may be safer and
more efficacious than those currently available. The growth of
such vaccine vectors on a continuous, consistent, expandable, and
more-readily-certifiable cell line should ultimately facilitate their
production for use in humans. The establishment of a genetic
complementation system for MVA now allows for genes, other
than udg, to be deleted from the viral genome to pursue hypothesis-
driven efforts to maximize vector immunogenicity. As a result, the
methods we have developed increase the facility with which the
biology of MVA and its interactions with host cells and host
organisms can now be studied. The knowledge gained from such
studies promises to enhance our ability to derive novel MVA




All animal studies were performed in accordance with animal
welfare protocols approved by Emory University.
Viruses
MVA (p579), generously provided by B. Moss (National
Institutes of Health), was amplified on primary CEFs or DF-1
chicken embryo fibroblasts as indicated. The conditional-lethal
vaccinia virus mutant ts4149, which harbors a temperature-
sensitive mutation in the D4R (uracil-DNA-glycosylase) open
reading frame, was kindly provided by G. McFadden (University
of Western Ontario) [51]. Virus stocks were prepared as lysates of
infected cells that were subsequently clarified via centrifugation
(800 g). Infectious titers of virus stocks were determined via
TCID50 assay on primary CEFs (where indicated) or via plaque
assay on DF-1 cell monolayers. During the course of this study,
several MVA recombinants were generated and the genotypes of
these recombinant viruses, with regard to uracil-DNA-glycosylase
(udg), gfpzeo (gz), and HIV-gag transgene (gag) are summarized as
follows: vDG001 (gz
+), vDG013 (Dudg, gz
+), vDG014 (Dudg, gz
+);
vDG027 (Dudg, gz






+). Viruses vDG021 and vDG022 express a synthetic, codon-
optimized, subtype-B consensus HIV-gag gene (GenBank
AY531263) and gfpzeo from independent early (modified H5) viral
promoters recombined into the MVA deletion-III site. Virus
MVA-lacZ expresses lacZ under the control of a modified H5 viral
promoter recombined into the MVA deletion-III site. Uracil-
DNA-glycosylase-deletion recombinants were propagated and
titered on complementing DF-1-derived cell lines (as described).
For use in animal studies, virus stocks underwent purification via
centrifugation through a 36% sucrose cushion prior to resuspen-
sion in PBS and titration via plaque assay on a commonly
permissive cell line.
Cells
The UMNSAH/DF-1 (DF-1) chicken embryo fibroblast cell
line [40,41], kindly provided by H. Varmus (Memorial Sloan-
Kettering Cancer Center, New York, NY) and currently available
through ATCC (#CRL-12203; Manassas, VA), was propagated in
Dulbecco’s Modified Eagle’s Medium (DMEM) that was supple-
mented with 10% heat-inactivated fetal bovine serum (FBS;
HyClone, Logan, UT), 100 I.U./ml penicillin (PEN), 100 mg/ml
streptomycin (STREP), and 2 mM L-glutamine (GLUT). Primary
chicken embryo fibroblasts (CEF) prepared from 8–11 day
embryos were obtained from Charles River SPAFAS, Inc.
(Preston, CT) and propagated in Basal Medium Eagle (Gibco/
Invitrogen) that was supplemented with 5% FBS, PEN, STREP,
and GLUT. All DF-1-derived cell lines (described below) were
propagated in DF-1 growth medium that was supplemented with
300 mg/ml G418 Sulfate. BHK-21 cells were obtained from
ATCC (#CCL-10) and propagated in Eagle’s MEM supplement-
ed with 10% FBS, PEN, STREP, GLUT, non-essential amino
acids, and 1 mM sodium pyruvate. HeLa cells were obtained from
ATCC and propagated in suspension culture in MEM Spinner
media (Quality Biologicals, Inc) supplemented with 5% heat-
inactivated horse serum, PEN, STREP, and GLUT. All tissue
culture growth media and supplements were obtained from
Mediatech (Herndon, VA) unless noted otherwise. Zeocin was
purchased from Invitrogen (Carlsbad, CA).
Generation of DF-1-derived cell lines
To allow generation of DF-1-derived cell lines that constitutively
express UDG
MVA, the pCAN gene-expression vector was
constructed for use in avian cells by subcloning a 1.7 kb CMV
IE-chicken ß-Actin promoter/enhancer element (kindly provided
by J. Jacob, Emory Vaccine Center [67]) into pNEB193 (New
England Biolabs, Beverly, MA) to yield pCMVACT193. Subse-
quently, a 2.3 kb BamHI SV40-Neo
R expression cassette was
subcloned from pIRES (BD Biosciences Clontech, Palo Alto, CA)
into pCMVACT193 to generate pCAN (CMV IE-chicken ß-
Actin/Neo
R).
The udg ORF (MVA nucleotides 92,417–93,073; Genbank
accession U94848) was amplified via polymerase chain reaction
from genomic MVA DNA with forward primer 59-tctcgagctcaAT-
GAATTCAGTGACTGTATCA-39 (initiator methionine codon
underlined) and reverse primer=59-cgcggtaccgtcTTAATAAA-
TAAACCCTTGAGC-39 (translation termination underlined; udg
ORF in capital letters) and cloned into pCR2.1 (Invitrogen) to
yield p2.1udgORF. The udg ORF was subsequently re-amplified
via PCR with forward primer 59-aaagcttagatctgccaccAT-
GAATTCAGTGACTGTA-39 (partial Kozak consensus in bold,
initiator methionine codon underlined) and reverse primer 59-
agcggccgctacgtaTTAATAAATAAACCCTTG-39 (translation ter-
mination underlined) to incorporate a partial translation initiation
consensus sequence immediately preceding the udg ORF [68].
This PCR product was cloned into the pCR-Blunt II-TOPO
vector (Invitrogen) to yield pDG100 and its nucleotide identity was
confirmed via DNA sequencing. The udg ORF was subsequently
positioned under the control of the CMV IE-chicken ß-Actin
promoter/enhancer element in the pCAN expression vector to
yield pCANudg.
DF-1-derived cell lines that constitutively express UDG
MVA
were generated by calcium phosphate-mediated transfection of the
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clonal selection of G418
R cells. G418
R cell lines were screened for
their ability to complement the growth of ts4149, a vaccinia virus
mutant that harbors a temperature-sensitive mutation in the udg
(D4R) gene, at the non-permissive temperature of 39.5uC [51,53].
The G418
R cell line that exhibited the highest level of
complementation, designated CAN20, was subsequently used to
generate and propagate udg-deletion recombinants of MVA (see
below).
Construction of MVA transfer vectors
MVA deletion site III vectors: pG06dH5, pG06dH5gz. A
vector to direct recombination of two gene expression cassettes
under the control of early viral promoters into MVA deletion site
III was constructed by replacing the synthetic double promoter in
plasmid pG06 [69] with bidirectional early (modified H5) viral
promoters. Two early viral (modified H5) promoters flanked by
restriction endonuclease sites (PmeI, ApaI, PacI, Eco47IIIrpH5–
StuI; StuI –pH5RNaeI, MluI, SacII, SacI) were generated by







ACAA-39 (upper case denotes promoter sequence, italics denote
regions of oligonucleotide complementarity). Single strand
overhangs of ligated oligonucleotides were filled in using Taq
polymerase and these dsDNA products were cloned into pCR2.1
(Invitrogen) to generate vectors pTA-H5anti and pTA-H5sense,
respectively. Modified H5 promoters were assembled into a
bidirectional promoter element via ligation of the 3.1 kB StuI/
BglII fragment of pTA-H5sense and 1.0 kB StuI/BglII fragment of
pTA-H5antitogeneratepTA-dH5.Thedoublesyntheticpromoters
of pG06 were removed via digestion with PmeI and SacI and
replaced with an EcoRV-SacI fragment containing the bidirectional
modified H5 promoter element from pTA-dH5 to yield MVADIII
transfer vector pG06dH5.
The gfpzeo ORF was amplified from pTracer-SV40 (Invitrogen)
via PCR with forward primer 59-aatcgcgaATGGCGGTAGAA-
AAAATG-39 and reverse primer 59-tacgtagaaaaaTCAGTCC-
TGCTCCTC-39 (upper case denotes gfpzeo ORF, italics denote
early vaccinia virus early gene transcriptional stop signal [70]).
The 1.1 kB NruI/SnaBI-digested gfpzeo fragment was cloned into
NruI/SnaBI-digested pG06dH5 to position the gfpzeo ORF under
the control of –pH5Rto yield vector pG06dH5gz. The transfer
vector pG06dH5gz was subsequently used to generate the viral
recombinant MVA-gz (vDG001) as described below.
udg deletion vector: pDudgdloxPH5gz. Genomic regions
flanking the udg ORF were amplified via PCR from MVA DNA.
The left flanking region was amplified with forward primer
59-aagagctcATATTGTGACTCCAGATACATATGGA-39 and
reverse primer 59-aaactagtCATTATATCAAATTAGATACCT-
TTTTATACG-39; the right flanking region was amplified with
forward primer 59-aactcgagAATGCTTTAGTGAAATTTTA-
ACTTGTGTTC-39 and reverse primer 59-aaggtaccTCC-
TAGTACCTACAACCCGAAGAG-39 (upper case denotes
MVA sequences, lower case denotes appended restriction
endonuclease sites). These genomic regions flanking udg were
individually cloned into the pCR-BluntII-TOPO vector and
verified via DNA sequencing. The right and left udg flanks were
sequentially cloned into pBluescriptII(SK+) (Stratagene) as XhoI-
KpnI and SacI-SpeI fragments, respectively, to yield plasmid
pBSudgLFRF. To position a gfpzeo expression cassette between two
loxP sites, plasmid pMS102 (kindly provided by J. Murray,
University of Cambridge [71]) was first digested with SnaBI and
EcorRV and religated to render a unique XbaI site between the
two loxP elements in this plasmid construct (pMSD102). A 1.2 kb
StuI-SnaBI pH5-gfpzeo expression cassette from pG06dH5gz was
blunt cloned in both leftward and rightward orientations into the
Klenow-filled XbaI site in pMSD102 to yield plasmids
pMSD102H5GZ.1, -.4, respectively. To construct transfer
vectors that direct the replacement of the udg ORF with a gfpzeo
expression cassette, SpeI-BglII fragments (containing loxP-flanked
pH5-gfpzeo) were subcloned from pMS102DH5GZ.4 and
pMSD102H5GZ.1 into SpeI-BamHI linearized pBSudgLFRF to
generate plasmids pDudgdloxPH5GZ-A, -B, respectively. Transfer
vectors pDudgdloxPH5GZ-A and pDudgdloxPH5GZ-B, which
differ only in the orientation of the gfpzeo expression cassette,
were subsequently used to generate MVADudg recombinants
vDG013 and vDG014, respectively, as described below.
Generation and isolation of recombinant MVAs
Recombinant MVAs were generated via homologous recombi-
nation by infecting 2610
6 permissive cells at MOI=0.05 for
1.5 hours followed by transfection of 1 mg MVA transfer vector
(supercoiled plasmid DNA) via Effectene (Qiagen, Valencia, CA)
according to the manufacturer’s protocol. At 48 hours following
infection, progeny viruses were released from infected cells via lysis
(1 freeze/thaw cycle followed by sonication) and were plated at
various dilutions onto monolayers of permissive cells (DF-1 or DF-
1-derived cell lines, as indicated). Recombinant gfpzeo
+ viruses
were selected for by application of an agarose overlay (1% low-
melting agarose/1XDMEM (GibcoBRL)) that was supplemented
with 2% FBS, 100 I.U./ml PEN, 100 mg/ml STREP, and
200 mg/ml Zeocin (Invitrogen). Recombinant viruses were
identified as foci of GFP
+ cells that were readily detected by 2
days following infection using fluorescence microscopy. Recombi-
nant viruses were plaque purified through at least 3 rounds of
Zeocin selection and analyzed by diagnostic Southern blots to
ensure clonality. MVA recombinant MVA-gz (vDG001) was
generated and propagated on DF-1 fibroblasts. Udg-deletion
recombinants vDG013 and vDG014 were generated and
propagated on the udg-complementing CAN20 cell line.
Southern blotting
DNA for Southern blot analyses was isolated from infected cells
following cell lysis in buffer containing 20mMTrisHCl (pH=8.0),
10 mM EDTA, and 0.75% SDS. Cell lysates were incubated
overnight with 20 mg/ml proteinase K at 37uC and DNA was
isolated by phenol/chloroform extraction and ethanol precipita-
tion. Following restriction endonuclease digestion, DNA samples
were electrophoresed through 0.7% agarose gels, and transferred
to Nytran SuPerCharge membrane (Schleicher and Schuell)
according to standard procedures [72]. Plasmid probes were
labeled with digoxygenin-dUTP via random-prime labeling
(Roche; Indianapolis, IN), hybridized to membranes [73] and
immunologically detected via chemiluminescence with CSPD
substrate (Roche) and BioMax film (Kodak).
Determination of viral growth kinetics
Primary CEFs (p11), DF-1 fibroblasts, and BHK-21 cells were
infected with 3 infectious units of MVA per cell and incubated at
37uC in low serum (2% FBS) growth media. Infected cell cultures
were frozen at indicated times following infection and subsequent-
ly thawed, sonicated, and clarified by centrifugation (800 g). MVA
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assay on DF-1 fibroblasts, as indicated.
Metabolic labeling of infected-cell proteins
Two million cells were infected with MVA or MVADudg
(vDG014) at a ratio of 10 PFU per cell. Following 90 min
adsorption, cells were washed with PBS and incubated in low-
serum (2%) DMEM culture medium in the absence or presence of
150 mM Cytosine ß-D-Arabino-Furanoside (AraC; Sigma), as
indicated. For metabolic labeling, cells were washed once with
PBS and then incubated for 30 min (prior to indicated timepoint)
at 37uC with 1 ml Methionine-free DMEM (Sigma) that was
supplemented with 2% FBS, 100 I.U./ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine, 10 mM HEPES (pH 7.4), and
90 mCi
35S-TransLabel (ICN) per 2610
6 cells. Proteins were
resolved by SDS-PAGE and labeled proteins were visualized via
autoradiography.
BrdU-labeling of DNA
DF-1 cells were grown on glass coverslips and infected with
MVA or vDG020, a udg-deletion MVA recombinant that
expresses RFP and puromycin-resistance gene products from
early modified H5 promoters at the MVADIII locus) at a ratio of
10 PFU per cell, or were mock-infected, in low-serum (2% FBS)
culture medium in the presence or absence of 150 mM AraC. Cells
were labeled between 2–6 hours following infection via incubation
with culture medium that was supplemented with 10 mM BrdU
(Becton-Dickinson, BD). Cells were then fixed and permeabilized
(cytofix/cytoperm, BD), treated with DNase (300 mg/ml in DPBS
with Ca
+2,M g
+2 for 1 hour at 37uC), stained with primary anti-
BrdU-FITC or isotype (mouse IgG1-FITC) control antibodies
(BD) and secondary anti-mouse-Ig-fluorescein (Amersham) and
observed via fluorescence microscopy.
Murine Studies
Intracellular Cytokine Assay of MVA-Specific CD8+ T
Cells. Female C57Bl/6J mice (The Jackson Laboratory, Bar
Harbor, ME) aged 6–8 weeks were immunized by intraperitoneal
injection of 10
6 PFU MVA or MVADudg (vDG027), as indicated.
Seven days later, the reactivity of CD8+ splenocytes to a panel of
individual peptides representing previously identified vaccinia
virus CD8+ T cell epitopes [55], was determined by intracellular
cytokine staining and flow cytometric analysis. Briefly, dissected
spleens were manually disrupted into cellular suspensions and red
blood cells were lysed using NH4Cl buffer (Sigma). Remaining
cells were enumerated and samples of one million splenocytes
were stimulated with 0.5 mM peptide in the presence of
GolgiPlug (Becton Dickinson [BD]) for 5 hours at 37uC.
Peptides used for stimulation represent H2
b-restricted vaccinia
virus CD8+ T cell determinants A3L270–277 (KSYNYMLL),
A42R88–96 (YAPVSPIVI), B8R20–27 (TSYKFESV), K3L6–15
(YSLPNAGDVI), or A19L47–55 (VSLDYINTM) [55,74].
Following stimulation, cells were surface-stained with
fluorescently labeled antibodies FITC-CD3 (2C11) and PerCP-
CD8 (53-6.7), then permeabilized using cytofix/cytoperm (BD)
and stained with antibody APC-IFNc (XMG1.2); all antibodies
were purchased from BD. Finally, cells were fixed with 2%
formaldehyde, 0.1% sodium azide in PBS, and analyzed on a
FACScalibur (BD). For analysis (FlowJo, Treestar, Inc),
splenocytes were gated on lymphocytes by forward/side scatter
and T cells by CD3 positivity prior to gating on CD8 and IFNc.
Determination of MVA-Specific Neutralizing Antibody
Titers. C57Bl/6J mice (The Jackson Laboratory, Bar Harbor,
ME) aged 6–8 weeks were immunized by intraperitoneal injection
with MVA or MVADudg (vDG027) at a dose of 10
4–10
8 PFU, as
specified. At 28 days following immunization, mice were sacrificed
and blood collected via cardiac puncture. To prepare serum,
blood was allowed to clot overnight at 4uC, clarified by
centrifugation, and heat-inactivated at 56uC for 30 minutes.
Serum samples were assayed in duplicate by a flow cytometry
(GFP)-based neutralization assay adapted from that described by
Earl, et al [75]. Briefly, serial 2-fold dilutions of sera were
incubated for 1 h at 37uC with a fixed volume of MVA-gz, which
had been previously determined via titration to infect 25–30% of
1610
5 HeLa cells in suspension. Serum-virus mixtures were then
added to 1610
5 HeLa cells and incubated for 16 h at 37uC.
Samples were fixed by adding an equal volume of 1%
formaldehyde in PBS, processed on a FACScalibur flow
cytometer (BD) and analyzed (FlowJo) to determine the
percentages of GFP+ HeLa cells. EC50 values were calculated
by nonlinear regression analysis of the replicate dilution series for
each sample using Prism 4 software (GraphPad Software, Inc.).
Rhesus Macaque Studies
Immunizations. Male rhesus macaques, aged 3.5–5 years
were immunized with a total of 2610
8 PFU of MVADudg-gag or
MVA-gag that was delivered by a split route: 1610
8 PFU
intradermally and 1610
8 PFU intramuscularly into alternate
thighs.
Intracellular Cytokine Assay. Cryopreserved PBMCs were
thawed and rested overnight at 37uC in complete cell culture
medium. Replicate cultures of 2610
6 PBMCs were cultured for
6 hours in the absence (unstimulated) or presence (stimulated) of a
single pool of HIV Gag peptides (15-mers, overlapping by 11; NIH
AIDS Research & Reference Reagent Program), which were
identically matched to the Gag antigen expressed by both MVA
vectors, at a final concentration of 2 mg/peptide/ml. Cytokine
secretion was blocked during the final 4 hours by the addition of
GolgiPlug (BD Biosciences). Cells were stained with Alexa-430
(Invitrogen) to enable subsequent live/dead discrimination,
permeabilized and stained with a cocktail of fluorophore-labeled
antibodies, and analyzed on an LSR-II flow cytometer (BD
Biosciences). The antibody staining panel consisted of CD4-FITC
(L200; BDP), IL2-PE (17H12; BDP), CD8ß-ECD (2ST8.5H7;
BC), CD69-PECy5.5 (CH/4; CAL); IFNc-APC (B27; BDP),
CD14-APCCy7 (M5E2; BIO), CD20-APCCy7 (2H7; BIO), and
CD3-PacificBlue (SP34-2; BDP) [BDP=BD Pharmingen;
BC=Beckman Coulter; CAL=Caltag; BIO=Biolegend]. Data
were analyzed using FlowJo analysis software (Tree Star, Inc.).
The hierarchical gating strategy used to determine the frequencies
of cytokine-positive CD8 and CD4 T cells is illustrated (Figure S1).
For each T cell:cytokine combination analyzed, the means of
replicate unstimulated PBMC samples were subtracted from the
corresponding mean of replicate Gag-stimulated PBMCs to yield a
single value per macaque per timepoint. Statistical comparison of
MVADudg-gag and MVA-gag groups was performed by
nonparametric Mann-Whitney analysis using Prism software
(GraphPad Software, Inc.).
Determination of HIV Gag-Specific Binding Antibody
Titers. Maxisorb ELISA plates (Nunc, Rochester, NY) were
coated overnight (4uC) with baculovirus-expressed recombinant
HIV Gag protein (HIV-1IIIBp55Gag; #3276; NIH AIDS
Research and Reference Reagent Program) in a 50 ml volume
per well at a concentration of 1 mg/ml in 0.1 M sodium
bicarbonate buffer (pH 9.5). Plates were washed three times with
wash buffer (KPL, Inc; Gaithersburg, MD), and blocked with 10%
fetal bovine serum in wash buffer for 1 hour at room temperature.
Macaque plasma samples were diluted 1:25 with blocking solution.
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wells of the Gag-coated ELISA plates for 2 hours at room
temperature. Plates were washed 5 times with wash buffer
(200 ml/well) followed by incubation for 45 minutes at room
temperature with 50 ml volume per well of the 2u polyclonal anti-
rhesus-HRP antibody (Accurate Chemical and Scientific Corp.,
Westbury, NY) at 1:8,000 dilution in blocking solution. Plates were
washed seven times with wash buffer and incubated with TMB
(3,3,5,59-tetramethylbenzidine) Microwell Peroxidase substrate
system (2-C) (KPL, Inc.) at 50 ml per well, for 20 minutes at
room temperature. The reaction was stopped by the addition of
1 M phosphoric acid (25 ml per well). Absorbance (450 nm) values
were obtained via plate reader, corrected for blank-well
absorbance, and the values for replicate samples were averaged.
For each individual macaque, post-immunization data were
normalized to the pre-immunization baseline by subtraction of
the corresponding pre-immunization Gag-ELISA value.
Determination of MVA-Specific Binding Antibody
Titers. Maxisorb ELISA plates (Nunc, Rochester, NY) were
coated overnight with 5610
6 PFU of sucrose-purified MVA per
well, washed four times with PBS, and blocked 1.5 hours at 37uC
with 4% BSA/17% fetal bovine serum in PBS. Serial 1:2 dilutions
of test serum (in duplicate) were incubated in MVA virion-coated
plates for 1.5 hours at 37uC. Plates were washed 5 times with PBS
(200 ml/well) followed by incubation for 1.5 hours at 37uC with
polyclonal anti-rhesus-HRP antibody (Accurate Chemical and
Scientific Corp., Westbury, NY) at 1:10,000 dilution in blocking
solution. Plates were washed five times with PBS and incubated
with One-Step TMB (3,3,5,59-tetramethylbenzidine) solution
(Pierce, Rockfore, IL) for 20 minutes at room temperature. The
reaction was stopped with 4N H2SO4. A450nm values were
obtained via plate reader and were corrected for blank-well
absorbance. Corrected absorbance data were analyzed as a
function of serum dilution by non-linear regression analysis
using Prism software (GraphPad Software, Inc.). For each
individual sample, the MVA-specific ELISA titer is reported as
the serum dilution corresponding to an A450nm value of 0.3, as
interpolated from the fitted curve (R
2.0.97).
Determination of MVA-Specific Neutralizing Antibody
Titers. Titers of MVA-specific neutralizing antibodies were
determined with an MVA-lacZ infection-inhibition assay adapted
from Manischewitz, et al [76]. This assay, which is performed in
96-well plates, provided a relatively higher throughput assay than
did the MVA-gfpzeo assay described above, and was therefore
employed for analyzing the samples from the macaque
immunization trial. Briefly, serial 1:2 dilutions of heat-
inactivated test sera (50 ml volume) were mixed with equal
volumes of DMEM containing 2.5610
4 PFU MVA-lacZ and
incubated for 1 hour at 37uC. At the end of this period, 1610
5
DF-1 cells were added per well and incubated for an additional
16 hours at 37uC. Culture supernatant was removed and the cells
were washed twice with PBS, followed by lysis via addition of
100 ml Reporter Lysis Buffer (Promega) per well and incubation
for 15 minutes at room temperature. Plates were centrifuged for
5 minutes and 50 ml aliquots of lysates were transferred into new
96-well plates. ß-gal activity was assayed by addition of 50 ml
ONPG solution (4.3 mM ONPG, 0.2 M NaH2PO4, 0.1 M
Na2HPO4, 4 mM MgCl2, 0.1 M ß-mercaptoethanol) and
incubation for 30 minutes at 37uC. The reaction was stopped by
adding 150 ml1MN a 2CO3 per well. Absorbance readings of
samples were made at 420 nm and corrected for blank-well
absorbance. Corrected absorbance data were analyzed as a
function of serum dilution by non-linear regression analysis
using Prism software (GraphPad Software, Inc.). For each
individual sample, the MVA-specific NAb titer is reported as the
serum dilution corresponding to the best-fit EC50 value.
Supporting Information
Figure S1 Gating Strategy and Exemplary Intracellular Cyto-
kine Assay Data
Found at: doi:10.1371/journal.pone.0005445.s001 (0.25 MB
PDF)
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